{"name":"Mylan Pharma UK Ltd.","slug":"mylan-pharma-uk-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Revefenacin Inhalation Solution","genericName":"Revefenacin Inhalation Solution","slug":"revefenacin-inhalation-solution","indication":"Other","status":"phase_1"},{"name":"Placebo inhalation solution QD","genericName":"Placebo inhalation solution QD","slug":"placebo-inhalation-solution-qd","indication":"Other","status":"phase_3"},{"name":"Seretide™ Accuhaler™","genericName":"Seretide™ Accuhaler™","slug":"seretide-accuhaler","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Revefenacin Inhalation Solution","genericName":"Revefenacin Inhalation Solution","slug":"revefenacin-inhalation-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo inhalation solution QD","genericName":"Placebo inhalation solution QD","slug":"placebo-inhalation-solution-qd","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.","indications":[],"catalyst":""},{"name":"Seretide™ Accuhaler™","genericName":"Seretide™ Accuhaler™","slug":"seretide-accuhaler","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPM083QTZjamg3THBPWHQwWTBxSXhJMkFXRzk2Uk5aVkxDb0lFQ1JTcmVBVjZzSDRVQ29QUUpLN3hPTmxEdldud0QzX0p2V3JEMUNKbDZzWFFrb3pJQjR2U0hkY3JTOTFaeGlHS3k2QTlMdFVmeWtHTTJGRlVteVJnRXJZSUZiY1VVTndCUjFQZTc3X19nY004RzN5VVZiem1PdzZldjllRlFnbzhVSXRiY0haOA?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo Finance","summary":"Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More - Yahoo Finance","headline":"Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOX21nck5mc2o1cEtET1pfZGVtQVpYMnI1MmYzMlBoUGtMUTdtT000ZW5NbGZZYUxFelJCWlZBZ0twYVlndk84QzAwVVJPQ1NtRWVhN2hRdC1ZLTJMc3pkTUFjOTBZcU5fdGZORlNkWE41MVd2TEdQSTR4Zk1hc1BZVHBn?oc=5","date":"2025-12-16","type":"regulatory","source":"Fact.MR","summary":"Demand for Artemisinin Combination Therapy in UK | Global Market Analysis Report - 2036 - Fact.MR","headline":"Demand for Artemisinin Combination Therapy in UK | Global Market Analysis Report - 2036","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPMzcyVHkzSUFySWxTdlZ6UEJNdTF2NGpNZFhVTFlKQ2ptT2Rvc3N5TjlUR3d6WmRiUmZlWm5FaDdiRVJrOWwtR2JXWEgyN3JCM0hyWkpWc3R4RUFVc29TTWR2NUo3UU5jeUZEdU0yTXBFNWV5N3YxSS1QNDBBQXl6YW9GTXRpYlp0YlViRzZabE1zSTF5ZXhfMjNCWjZuTnQzYzZsVXZyS2JvckR6UWVUN0h4Wkt0ZzFfYXRhVGhSR0U4NU5NZ0F4VHZzSHJ2OVYtRjBYdVR2NFFKUzhQ?oc=5","date":"2025-03-21","type":"patent","source":"Wolters Kluwer","summary":"Patent case: Biogen MA Inc. vs. Sandoz B.V., Neuraxpharm Pharmaceuticals S.L. and Mylan B.V., Netherlands - Wolters Kluwer","headline":"Patent case: Biogen MA Inc. vs. Sandoz B.V., Neuraxpharm Pharmaceuticals S.L. and Mylan B.V., Netherlands","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPOE5Sbld0eGd0VU9HeXFsWXhnX3piaGZVSVNVRHhIcTk1U0lJQm84Nmw1OUxsWXdKVDM0MDc5VjRqYzB2bkxoSEt3UHJGNTJQNDA4ZkpuaGVlV2hkb01vdDdwVVRrVlVUWUFIR3dMcVZTM2pYR3VkNHE0cGRDcURrbzhWMXlVcmpKaHlTaG1iMy1DWkNGaVZEYmlMZE44Qnk0OTUwQ0pScXdVT3NVZlZoSk1sQjFWRGR6QzhLNUwxTi0xM3JVR2d3RGhleWt0a1Z6b0hxUUgxejc?oc=5","date":"2025-03-17","type":"pipeline","source":"Top Class Actions","summary":"$73.5M Mylan Pharmaceuticals EpiPen monopoly class action settlement - Top Class Actions","headline":"$73.5M Mylan Pharmaceuticals EpiPen monopoly class action settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOVTFpNU0xM1pUVy10bmRzZWtrbWdCeTFzeXV2bm9kTTFSWnBIMVdNaE8xY01VeWNrcXZXUVRTQjFZRndoUXhHZDYzOF9oSTQ5Z0NXZVhwQW1uMnhuSFQ2OUI0ZUVVTFRuSUx5MnZiU3N4ZVhfQ2Q5eWhvVzBORm1pRFluMGtJWFZwNVdTR1ZNVk5WbnRNOHcwazlwZ9IBWEFVX3lxTFA4OXpNZlo3azRhOVpnbE5UZGpWVHB1c0s0TFRURTZOUVc3aUxYTlNLWW1NT1pDSW94ZXNaeWRQeWxKdlNLZFE1blVGMGkyZTU3cDFzTUpzODY?oc=5","date":"2025-03-12","type":"patent","source":"Law360","summary":"Law360 Cheat Sheet: Novartis' Fight Over Generic Entresto - Law360","headline":"Law360 Cheat Sheet: Novartis' Fight Over Generic Entresto - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNRlA3MldGV1BTUTgzeWhyZ0owcGtYeDFRZWprSjZfLVJMZGlOTE9qMU4tNWo5N3ZEajlEVUlIT1M5TlN0b29wVjNUdTM3c2Vpem1aeTFjNS1YVUVEd0g1b0NyalltUGZnbHkxYlV4MC1OWmpFYVRjZExDT3RVOHZOTmNB?oc=5","date":"2025-01-14","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 13, 2025 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 13, 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQTlh0QllQTVNwVWVCNG5kbmdiNC0tN3hkc3pwV1BjQTJTZl9UTUZuTTE0dUdwaXBUVzNTNTJncFdoWUY0dFRQeE5MbmwtNnNJYU1MeHdmTVYxZEhoM1pscG9wWHdwLVdlYlJ6VkJRaHJ5UUEzdDRJVFFZekR5T0V6dDhUcUd4dnpQMklpZHgybHBGcTdNYnh2N2w4bm9saS1Fcy1GNm5ibTBhOC1nanZoRkJnSHhuNmtkOXlVQWxKTDlCbXVKTW5SdWZibU1PQlZ3TXVZU0dfaGNzUHMtRHJLdA?oc=5","date":"2024-11-16","type":"pipeline","source":"www.hoganlovells.com","summary":"Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional - www.hoganlovells.com","headline":"Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPbGV3NHM1ZkNNYnl0Zlg0MHoyTWN2M09RaktpVUMwUk14UnMycG94TlcxODd6a3lqVjRIekU5T3ZUbmwtTndmVC10S0tETlllWHg4c3NrMzU0c1B0TTdELTdKZjI0Ty05NjRnUWpaNDlHcjI1UkZIZE14RmFqcV94dTNmYW9zVnloSEMybkxqRmY0eUJ0LWNWRExpc1doYVhQMkstaA?oc=5","date":"2024-11-05","type":"earnings","source":"BioSpace","summary":"Lacks Family Lawsuits Seek Share of Profits Stemming from HeLa Cells - BioSpace","headline":"Lacks Family Lawsuits Seek Share of Profits Stemming from HeLa Cells","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNRGI3M1BEajhtcFI5UFloMVg0eV9fcjFuRndub3M5cTA4aWFrRExoRmZDbmJaSTctWTRPYUZ1SU1hQ0VVdXFWdTVjX2ZHMWxwU1NOMGxZZEIzcU5TdnYtZzJfRHBxZU1rOEl3bTY1Qi0xN29taGc1TUxVOXBEQzhqR0ZrTmo3WFo0ejNGLXhzYmNHNHBnQm81aG13Qkh0YWFvb2FZeEZqcmNLWUVsWXh2MTRZa1NxYVl0WC1IdElyWU11OEtfUWtZ?oc=5","date":"2024-09-03","type":"pipeline","source":"Citeline News & Insights","summary":"Perrigo’s Tab Owed To Shareholders Nine Years After Spurning Mylan’s Hostile Takeover? $97M - Citeline News & Insights","headline":"Perrigo’s Tab Owed To Shareholders Nine Years After Spurning Mylan’s Hostile Takeover? $97M - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFA5S29nNV9GTm5aTE04MldqajlwYWlUQkg3NjVVc3RiN2FrTVVEeVNwRW9lcGVCekxsemxhcHlma0dwdnBxSzhsUEFrUEM0S3l4MGhQeGxhSjR6aG1ZeHpldEtLSHd4czhjNEJXaTRPSmVxUVJwNUtlRHVFOXI?oc=5","date":"2024-04-15","type":"earnings","source":"Fierce Pharma","summary":"The top 20 pharma companies by 2023 revenue - Fierce Pharma","headline":"The top 20 pharma companies by 2023 revenue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZ21NMEZfOFM3T3d5MGtWazZiQndXWVlOeGZGa0ctMWNwNldKLVRyLW1qTnpfOWJLakNsZjNCUXVJeTQtWGt2ZGhsd0x2RVVzVEhBZzR5a01qLWdfQjlUZDFuQ0gyNFNfOWEtZWZvbHJSb2ZFd0Q0ZWVPSTVGNU44cUctOTRidGswQzVz?oc=5","date":"2020-10-09","type":"pipeline","source":"Lexology","summary":"Case Summary : Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd - Lexology","headline":"Case Summary : Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQUGlGQ2ZVM0NmU1RJeHdmODZhVnVtT1NXSjhpZXZhOUpScGVrUkxWT2N0Q3MwV3V6U0VNMkkwbUlOa05rd1UzWE1HUHZzZ2lOdHhwMkt4ajFDcU5zVDNlb2pIWFBEd1A0c05qZ0s4S2Q3THRCNkc0ZTh4MWtEYndlT1o5Wmc4a3RpNDAyMi1majJGNGxmdkhqckQwaElWZDRhd1BjX29ldGFMWms4bjR5aUdHeUM1UHFZczZJUFRYemktckNpWEV1MTU4VGZhZEoxN0p6Q1pxU0RaYzdDN3pDNXdyUHZlYmpYbXIyQVludV9RVGhPLWFpODM0U2JoRGFtckY4b1d3UGRGRGZYVWFqYXdVaVJrMXhlVEFwZnFpQ0hvUWsxZURNcDRR?oc=5","date":"2020-06-11","type":"pipeline","source":"Herbert Smith Freehills Kramer","summary":"The rock misses its target in this story of “David and Goliath” – the UK High Court's consideration of interim injunctions in Neurim Pharmaceuticals v Mylan - Herbert Smith Freehills Kramer","headline":"The rock misses its target in this story of “David and Goliath” – the UK High Court's consideration of interim injunctio","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}